Alice S Chen-Plotkin

List of Publications by Citations

Source: https://exaly.com/author-pdf/4017521/alice-s-chen-plotkin-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97 papers	9,680 citations	47 h-index	98 g-index
116 ext. papers	12,078 ext. citations	9.9 avg, IF	5.84 L-index

#	Paper	IF	Citations
97	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*, **2017**, 89, 88-100	6.5	1691
96	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature*, **2010**, 466, 1069-75	50.4	844
95	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. *Lancet Neurology, The*, **2008**, 7, 409-16	24.1	542
94	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nature Genetics*, **2010**, 42, 234-9	36.3	361
93	TAR DNA-binding protein 43 in neurodegenerative disease. *Nature Reviews Neurology*, **2010**, 6, 211-20	15	322
92	The Post-GWAS Era: From Association to Function. *American Journal of Human Genetics*, **2018**, 102, 717-730	11	294
91	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. *Journal of Clinical Investigation*, **2011**, 121, 726-38	15.9	284
90	Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. *Journal of Biological Chemistry*, **2009**, 284, 8516-24	5.4	262
89	Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurology*, **2013**, 70, 1277-87	17.2	252
88	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain*, **2018**, 141, 2181-2193	11.2	245
87	APOE ε4 increases risk for dementia in pure synucleinopathies. *JAMA Neurology*, **2013**, 70, 223-8	17.2	243
86	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology*, **2012**, 79, 897-905	6.5	175
85	Longitudinal study of normal cognition in Parkinson disease. *Neurology*, **2015**, 85, 1276-82	6.5	144
84	TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. *Journal of Neuroscience*, **2012**, 32, 11213-27	6.6	143
83	The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. *Archives of Neurology*, **2010**, 67, 161-70		143
82	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. *Lancet Neurology, The*, **2015**, 14, 1002-9	24.1	141
81	Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. *Acta Neuropathologica*, **2010**, 119, 669-78	14.3	140

80	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. *Acta Neuropathologica*, **2016**, 131, 935-49	14.3	138
79	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *JAMA Neurology*, **2016**, 73, 1217-1224	17.2	120
78	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. *Alzheimer's and Dementia*, **2014**, 10, 477-484.e1	1.2	118
77	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. *Movement Disorders*, **2016**, 31, 95-102	7	113
76	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. *Movement Disorders*, **2017**, 32, 319-324	7	111
75	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. *Annals of Neurology*, **2011**, 69, 655-63	9.4	103
74	Genetic influences on cognitive decline in Parkinson's disease. *Movement Disorders*, **2012**, 27, 512-8	7	100
73	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. *Lancet Neurology, The*, **2017**, 16, 620-629	24.1	98
72	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathologica*, **2014**, 127, 407-18	14.3	97
71	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. *Human Molecular Genetics*, **2008**, 17, 1349-62	5.6	96
70	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. *JAMA Neurology*, **2019**, 76, 318-325	17.2	94
69	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. *Archives of Neurology*, **2011**, 68, 488-97		93
68	Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. *Neurobiology of Disease*, **2006**, 22, 233-41	7.5	92
67	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. *Annals of Neurology*, **2013**, 74, 119-27	9.4	90
66	Blood-based biomarkers for Parkinson's disease. *Parkinsonism and Related Disorders*, **2014**, 20 Suppl 1, S99-103	3.6	88
65	Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. *JAMA Neurology*, **2013**, 70, 852-8	17.2	87
64	Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. *JAMA Neurology*, **2013**, 70, 1411-7	17.2	87
63	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimer's Research and Therapy*, **2017**, 9, 89	9	85

62	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. *Acta Neuropathologica*, **2018**, 136, 363-376	14.3	83
61	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. *Acta Neuropathologica*, **2011**, 121, 373-80	14.3	82
60	Finding useful biomarkers for Parkinson's disease. *Science Translational Medicine*, **2018**, 10,	17.5	69
59	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. *Acta Neuropathologica*, **2010**, 120, 385-99	14.3	65
58	PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. *PLoS ONE*, **2011**, 6, e17951	3.7	64
57	Modeling kinetic rate variation in third generation DNA sequencing data to detect putative modifications to DNA bases. *Genome Research*, **2013**, 23, 129-41	9.7	63
56	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. *Movement Disorders*, **2014**, 29, 1809-15	7	62
55	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. *Acta Neuropathologica*, **2010**, 119, 111-22	14.3	56
54	The NINDS Parkinson's disease biomarkers program. *Movement Disorders*, **2016**, 31, 915-23	7	56
53	Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. *Movement Disorders*, **2015**, 30, 1648-56	7	50
52	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. *Alzheimer's and Dementia*, **2019**, 15, 55-64	1.2	50
51	What can biomarkers tell us about cognition in Parkinson's disease?. *Movement Disorders*, **2014**, 29, 622-33	7	48
50	A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. *American Journal of Human Genetics*, **2017**, 101, 643-663	11	46
49	CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. *Neurology*, **2018**, 90, e1038-e1046	6.5	43
48	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. *Journal of the Neurological Sciences*, **2013**, 333, 9-12	3.2	43
47	Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1303-1310	5.5	41
46	Unbiased approaches to biomarker discovery in neurodegenerative diseases. *Neuron*, **2014**, 84, 594-607	13.9	40
45	New York City COVID-19 resident physician exposure during exponential phase of pandemic. *Journal of Clinical Investigation*, **2020**, 130, 4726-4733	15.9	40

44	Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. *Human Molecular Genetics*, **2016**, 25, 2681-2697	5.6	38
43	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. *Biomarkers in Medicine*, **2017**, 11, 451-473	2.3	33
42	L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. *Nature Methods*, **2021**, 18, 631-634	21.6	30
41	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. *Movement Disorders*, **2015**, 30, 805-12	7	29
40	AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity. *Molecular Therapy*, **2019**, 27, 465-478	11.7	29
39	Age-correlated gene expression in normal and neurodegenerative human brain tissues. *PLoS ONE*, **2010**, 5, e13098	3.7	28
38	Cerebrospinal fluid -synuclein contributes to the differential diagnosis of Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1052-1062	1.2	27
37	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. *Annals of Clinical and Translational Neurology*, **2017**, 4, 15-25	5.3	26
36	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2016**, 3, 346-55	5.3	26
35	Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. *Nature Communications*, **2018**, 9, 4406	17.4	26
34	Regional brain amyloid- accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. *PLoS ONE*, **2017**, 12, e0177924	3.7	25
33	Caregiver report of apathy predicts dementia in Parkinson's disease. *Parkinsonism and Related Disorders*, **2015**, 21, 992-5	3.6	24
32	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. *Movement Disorders*, **2018**, 33, 289-297	7	24
31	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. *Annals of Neurology*, **2019**, 85, 801-811	9.4	23
30	Omics in Neurodegenerative Disease: Hope or Hype?. *Trends in Genetics*, **2020**, 36, 152-159	8.5	20
29	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. *Acta Neuropathologica Communications*, **2013**, 1, 36	7.3	19
28	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. *PLoS ONE*, **2016**, 11, e0147319	3.7	18
27	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. *PLoS Medicine*, **2019**, 16, e1002931	11.6	17

26	Delayed leukoencephalopathy after hypoxic-ischemic injury. *Archives of Neurology*, **2008**, 65, 144-5		17
25	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. *Journal of Parkinson's Disease*, **2017**, 7, 385-395	5.3	15
24	A growth-factor-activated lysosomal K channel regulates Parkinson's pathology. *Nature*, **2021**, 591, 431-437	50.4	15
23	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. *Parkinsonism and Related Disorders*, **2018**, 46 Suppl 1, S15-S18	3.6	14
22	Hypertrophic pachymeningitis and cerebral venous sinus thrombosis in inflammatory bowel disease. *Journal of Clinical Neuroscience*, **2010**, 17, 1454-6	2.2	14
21	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. *Movement Disorders*, **2020**, 35, 1618-1625	7	12
20	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. *Movement Disorders*, **2017**, 32, 1636-1640	7	12
19	Statins and Cognition in Parkinson's Disease. *Journal of Parkinson's Disease*, **2017**, 7, 661-667	5.3	10
18	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. *Movement Disorders Clinical Practice*, **2019**, 6, 440-445	2.2	9
17	Resident physician exposure to novel coronavirus (2019-nCoV, SARS-CoV-2) within New York City during exponential phase of COVID-19 pandemic: Report of the New York City Residency Program Directors COVID-19 Research Group **2020**,		9
16	Genetic Modifiers in Neurodegeneration. *Current Genetic Medicine Reports*, **2018**, 6, 11-19	2.2	8
15	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. *Annals of Clinical and Translational Neurology*, **2020**, 7, 2342-2355	5.3	8
14	Updating Our Definitions of Parkinson's Disease for a Molecular Age. *Journal of Parkinson's Disease*, **2018**, 8, S53-S57	5.3	6
13	Demyelinating polyneuropathy and herpes simplex lumbosacral radiculitis in a patient with chronic HIV infection. *Aids*, **2007**, 21, 1663-4	3.5	5
12	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. *Acta Neuropathologica*, **2020**, 140, 449-461	14.3	3
11	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. *Acta Neuropathologica*, **2021**, 142, 629-642	14.3	3
10	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. *Movement Disorders*, **2021**,	7	3
9	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. *Neurology: Clinical Practice*, **2021**, 11, 105-116	1.7	2

8	Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease: A Cross-sectional Study.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	2
7	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. *Journal of Parkinson's Disease*, **2021**, 11, 757-765	5.3	1
6	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. *Journal of Parkinson's Disease*, **2021**, 11, 737-745	5.3	1
5	LRRK2 and survival in progressive supranuclear palsy. *Lancet Neurology, The*, **2021**, 20, 83-84	24.1	1
4	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.. *Molecular Neurodegeneration*, **2022**, 17, 29	19	1
3	Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. *Movement Disorders*, **2015**, 30, 1975-6	7	
2	Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".. *Movement Disorders*, **2022**, 37, 436-437	7	
1	Of mice and men: What a mouse model of microglial C9ORF72 deficiency does-and does not-tell us about human neurodegenerative diseases. *Neuron*, **2021**, 109, 2203-2204	13.9	